Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy

Rheumatology International

Volumn 34, Issue 2, 2014, Pages 221-225

  Kawashiri, Shin Ya ^a   Ueki, Yukitaka ^b   Terada, Kaoru ^b   Yamasaki, Satoshi ^a   Aoyagi, Kiyoshi ^a   Kawakami, Atsushi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b SASEBO CHUO HOSPITAL   (Japan)

Author keywords

Bosentan; Endothelin 1; Nitric oxide; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

BOSENTAN; ENDOTHELIN 1; NITRIC OXIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS;

AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; ENDOTHELIN-1; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84895789368     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2861-6     Document Type: Article

References (24)

1. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66:940-944
2. Mukerjee D, St. George D, Coleiro B, Knight C, Denton CP, Davar J, et al. (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62:1088-1093
3. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE (2003) Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123:344-350
4. Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351:1425-1436
5. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54:S78-S84
6. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493-2537
7. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620-628
8. Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, et al. (2010) Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 49:490-500
9. Hachulla E, Coghlan JG (2004) A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 63:1009-1014
10. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, et al. (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92:926-932
11. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V (2009) Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 48(iii):25-31
12. Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48(iii):3-7
13. Mehta S (2003) Sildenafil for pulmonary arterial hypertension: exciting, but protection required. Chest 123:989-992
14. Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980) Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum 23:581-590
15. Steen V, Medsger TA Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48:516-522
16. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (esc) and the European respiratory society (ers), endorsed by the international society of heart and lung transplantation (ISHLT). Eur Heart J 30:2493-2537
17. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111-117
18. Ueki Y, Miyake S, Tominaga Y, Eguchi K (1996) Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol 23:230-236
19. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. (1994) Circulating endothelin-1 levels in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction? J Rheumatol 21:1838-1844
20. Stewart DJ, Levy RD, Cernacek P, Langleben D (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114:464-469
21. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, et al. (2001) Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120:1562-1569
22. Kahaleh MB (1991) Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 34:978-983
23. Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H, et al. (1992) Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 19:1566-1571
24. Vizza CD, Letizia C, Petramala L, Badagliacca R, Poscia R, Zepponi E, et al. (2008) Venous endothelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. Regul Pept 151:48-53